- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02711267
Bioequivalence of Topical Acyclovir in Healthy Volunteers (FDA_BE1)
March 11, 2016 updated by: Medical University of Graz
An Exploratory Study to Evaluate Dermal Open Flow Microperfusion's (dOFM) Ability to Assess Bioequivalence and Non-bioequivalence of Topical Acyclovir Formulations in Healthy Volunteers
The overall aim of this clinical study is to investigate the ability of dermal open flow microperfusion to assess bioequivalence and non-bioequivalence of acyclovir formulations in the skin of healthy volunteers.
Study Overview
Status
Completed
Conditions
Detailed Description
This will be a single center, open label, exploratory research study to evaluate the BE of already marketed formulations of acyclovir in dermal interstitial fluid (ISF) in healthy volunteers using dOFM.
The study will be conducted at the Clinical Research Center at the Medical University Graz.
dOFM represents the most reliable way to sample interstitial fluid from skin, since it provides diluted but otherwise unchanged dermal interstitial fluid.
To assess BE and non-BE, we have designed the experiments in such a way that each subject can serve as its own control.
Each subject will have two sets of BE and non-BE pairs in parallel.
This study is designed to test dOFM, a new sampling method that allows measurement of skin penetration.
Measurement of skin penetration enables the reduction of the impact of inter-subject variability and therefore decreases the number of subjects needed to achieve statistical significance.
Study Type
Interventional
Enrollment (Actual)
36
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Styria
-
Graz, Styria, Austria, 8036
- Medical University Graz
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
21 years to 50 years (ADULT)
Accepts Healthy Volunteers
Yes
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Written informed consent must be obtained before any assessment is performed.
- Male and female subjects 21 to 50 years of age inclusive and in good health as determined by past medical history, physical examination, vital signs, electrocardiogram, and laboratory tests at screening.
- Able to communicate well with the investigator, to understand and comply with the requirements of the study.
Exclusion Criteria:
- Use of other investigational drugs at the time of enrollment, or within 30 days or 5 half-lives of enrollment, whichever is longer; or longer if required by local regulations, and for any other limitation of participation in an investigational trial based on local regulations.
- History of hypersensitivity to any of the study drugs or to drugs of similar chemical classes.
- Use of topical corticosteroids or systemic immunosuppression within the last 3 weeks (for topicals) or 3 months (systemic medication)
A history of clinically significant ECG abnormalities, or any of the following ECG abnormalities at screening or baseline.
- PR > 220 msec
- QRS complex > 120 msec
- Long QT syndrome
- QTcF > 430 msec males, > 450 females
- Pregnant or nursing (lactating) women, where pregnancy is defined as the state of a female after conception and until the termination of gestation, confirmed by a positive hCG (human chorionic gonadotropin) laboratory test (> 10 mIU/mL).
- Significant medical problems, including but not limited to the following: uncontrolled hypertension (≥160 systolic /95 diastolic mm Hg), congestive heart failure [New York Heart Association status of class III or IV].
- Screening total WBC count <3,500cells/µL, or platelets <140,000cells/µL or neutrophils <2,000cells/µL or hemoglobin <12 g/dL / <13.5g/dL for female / male.
- Active systemic infections during the last two weeks (exception: common cold) prior to enrollment.
- A febrile illness within 72 hours, or major dental work within 8 days, prior to first dosing.
- History of immunodeficiency diseases, including a positive HIV (ELISA and Western blot) test result.
- A positive Hepatitis B surface antigen (HBsAg) or Hepatitis C test result.
- Inability or unwillingness to undergo repeated catheterization and / or venipuncture (e.g., because of poor tolerability or lack of access to veins). Inability or unwillingness of having a skin biopsy if consent was given.
- Any medical or psychiatric condition or clinical laboratory abnormalities which, in the Investigator's opinion, would interfere with interpretation of study results and/or make the participant likely not to adhere to the protocol or complete the study per protocol.
- History of venous thrombosis or known genetic predisposition to thromboembolic events
- Subjects prone to keloid or hypertrophic scar formation or any wound healing disorder as visible by checking the vaccine insertion points on upper arm.
- Fear of needles (belonephobia)
- Recent (within the last three [3] years) and/or recurrent history of autonomic dysfunction (e.g., recurrent episodes of fainting, palpitations, etc).
- Not willing to avoid excessive sun exposure, steam baths, sauna, swimming and other strenuous activities during the study to ensure good scarring.
- Not willing to refrain from use of skin care products applied on application sites for at least 5 days prior to start of Visit 2.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: BASIC_SCIENCE
- Allocation: NON_RANDOMIZED
- Interventional Model: SINGLE_GROUP
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: Phase 1: Optimization Study
6 subjects will be included in this study, each with 3 application sites on the arm and 3 on the leg. 2 dOFM probes (OFM Probe) will be implanted per site resulting in 12 dOFM probes per subject (operated by OFM pump).
On each the arm and the leg the proximal and distal site of the 3 adjacent sites will be treated by 5% Zovirax® cream.
The central site on arm and leg will be left untreated in order to test a potential lateral carry-over of acyclovir from one application site to the other.
Blood samples will be taken to test for uptake into the blood stream and redistribution to other application sites.
|
(manufactured by GlaxoSmithKline Pharma in Canada, distributed in the USA by Valeant Pharmaceuticals North America LCC, Bridgewater,NJ 08807)
Other Names:
Sampling method for interstitial fluid
Other Names:
Sampling probe used during OFM
Other Names:
Pump used to operate OFM probes
Other Names:
|
EXPERIMENTAL: Phase 2: Formulation Study
6 subjects will be included in this study, each with 3 application sites on the arm and 3 on the leg. 2 dOFM probes will be implanted per site resulting in 12 dOFM probes per subject.
Different topical 5% acyclovir formulations currently available on the market will be tested.
One application site on the arm and one on the leg will be used for U.S. Zovirax® cream 5% application.
The remaining two application sites on the arm and the remaining 2 on the leg will be used to randomly administer two of the remaining formulations (5% Aciclostad cream, 5% Aciclovir cream 1A Pharma, 5% Zovirax® cream (Austria), 5% Zovirax Cold Sore Cream) according to an application pattern.
|
(manufactured by GlaxoSmithKline Pharma in Canada, distributed in the USA by Valeant Pharmaceuticals North America LCC, Bridgewater,NJ 08807)
Other Names:
Sampling method for interstitial fluid
Other Names:
Sampling probe used during OFM
Other Names:
Pump used to operate OFM probes
Other Names:
(STADA Arzneimittel GmbH, Vienna, Austria)
Other Names:
(1A Pharma GmbH, Vienna, Austria)
Other Names:
(GlaxoSmithKline Consumer Health Care, Brendfort, UK; Marketing authorization holder: Beeham Group PLC, Brendfort, UK)
Other Names:
(GlaxoSmithKline Pharma GmbH, Vienna, Austria)
Other Names:
|
EXPERIMENTAL: Phase 3: Pilot BE study
4 subjects will be included in the pilot BE study with 3 application sites on each leg. 2 dOFM probes will be implanted per site resulting in 12 dOFM probes per subject.
One reference drug product (R) and one test drug product (T) will be applied on the application sites in order to test for BE between duplicate sites with R applied, and to test for non-BE between application sites with R and T applied.
|
(manufactured by GlaxoSmithKline Pharma in Canada, distributed in the USA by Valeant Pharmaceuticals North America LCC, Bridgewater,NJ 08807)
Other Names:
Sampling method for interstitial fluid
Other Names:
Sampling probe used during OFM
Other Names:
Pump used to operate OFM probes
Other Names:
(1A Pharma GmbH, Vienna, Austria)
Other Names:
|
EXPERIMENTAL: Phase 4: Main BE Study
20 subjects will be included in the pilot BE study with 3 application sites on each leg. 2 dOFM probes will be implanted per site resulting in 12 dOFM probes per subject.
One reference drug (R) and one test drug (T) will be applied on the application sites in order to test for BE between duplicate sites with R applied and to test for non-BE between application sites with R and T applied.
|
(manufactured by GlaxoSmithKline Pharma in Canada, distributed in the USA by Valeant Pharmaceuticals North America LCC, Bridgewater,NJ 08807)
Other Names:
Sampling method for interstitial fluid
Other Names:
Sampling probe used during OFM
Other Names:
Pump used to operate OFM probes
Other Names:
(1A Pharma GmbH, Vienna, Austria)
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
AUC
Time Frame: during 12-36h of OFM-Sampling (post-dose)
|
Area under the dOFM acyclovir concentration curve (AUC) during 12/36h of OFM-Sampling (post-dose)
|
during 12-36h of OFM-Sampling (post-dose)
|
CMAX
Time Frame: during 12-36h of OFM-Sampling (post-dose)
|
Maximum observed dOFM acyclovir concentration (CMAX) during 12/36h of OFM-Sampling (post-dose)
|
during 12-36h of OFM-Sampling (post-dose)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
dOFM acyclovir concentration
Time Frame: during 12-36h of OFM-Sampling (post-dose)
|
during 12-36h of OFM-Sampling (post-dose)
|
|
TMAX
Time Frame: during 12-36h of OFM-Sampling (post-dose)
|
Time to reach maximum dOFM acyclovir concentration (TMAX)
|
during 12-36h of OFM-Sampling (post-dose)
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
January 1, 2014
Primary Completion (ACTUAL)
August 1, 2015
Study Completion (ACTUAL)
August 1, 2015
Study Registration Dates
First Submitted
July 29, 2015
First Submitted That Met QC Criteria
March 11, 2016
First Posted (ESTIMATE)
March 17, 2016
Study Record Updates
Last Update Posted (ESTIMATE)
March 17, 2016
Last Update Submitted That Met QC Criteria
March 11, 2016
Last Verified
March 1, 2016
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- FDA_BE1
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Dermatologic Disorders
-
Northwestern UniversityCompletedDermatologic DisordersUnited States
-
Pusan National University HospitalCompletedDermatologic Disorders | Injury Due to LaserKorea, Republic of
-
Sohag UniversityNot yet recruitingDermatologic Disorders With Heamatologic Malignancies PatientsEgypt
-
University of ViennaMedical University of ViennaCompletedDermatologic Disorders | Disorder of Cholesterol Metabolism
-
Stemedica Cell Technologies, Inc.Active, not recruitingDermatologic Disorders | Chronic Effect of Ultraviolet Radiation on Photoaged SkinUnited States
-
University of California, IrvineBeckman Laser Institute University of California IrvineRecruitingDermatologic DiseasesUnited States
-
DermTechRecruitingDermatologic DiseasesUnited States
-
University Hospital, Basel, SwitzerlandCompleted
-
University of ZurichCompletedDermatologic Disease of Inpatients in Internal MedicineSwitzerland
Clinical Trials on 5% Zovirax® cream
-
Shulov Innovate for Science Ltd. 2012Completed
-
AiCuris Anti-infective Cures AGNovella ClinicalCompletedHerpes LabialisUnited States
-
Sol-Gel Technologies, Ltd.CompletedActinic Keratosis (AK)United States
-
Shanghai Zhongshan HospitalRecruiting
-
KK Women's and Children's HospitalNot yet recruiting
-
DS BiopharmaCompletedAtopic DermatitisUnited States, Canada, South Africa
-
BioCis Pharma LtdCompleted
-
Encube Ethicals Pvt. Ltd.Novum Pharmaceutical Research ServicesCompletedScabiesUnited States, El Salvador, Puerto Rico
-
Microbio Co LtdNot yet recruiting
-
Loreal USACompleted